DJ-1 inhibitors with good pharmacokinetic (PK) and pharmacodynamic (PD) properties can be utilized for cancer therapy, while DJ-1 agonists that can cross the blood–brain barrier can serve as PD-treatment drugs. This evidence concerns the gene PARK7 and cancer.